Unknown

Dataset Information

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.


ABSTRACT:

Context

Metastatic medullary thyroid carcinoma (MTC) and radioactive iodine-refractory differentiated thyroid carcinoma (RAI-R DTC) have poor prognosis and limited treatment options. Selpercatinib (LOXO-292), a selective kinase inhibitor targeting the RET gene, has shown a 69% to 79% objective response rate in this cohort with benefits in other tumors including lung cancer harboring the same oncogenic driver. Published reports describe only 17% of patients experiencing gastrointestinal (GI) adverse effects (AEs), which is in contrast to our local experience.

Objective

Here we characterize the AEs and correlate them with radiological and histopathological findings.

Methods

Sequential patients enrolled in LIBRETTO-001 at Royal North Shore Hospital, Sydney, Australia, wi

SUBMITTER: Tsang V 

PROVIDER: S-EPMC9387698 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature